Reuters
A Food and Drug Administration panel on Thursday recommended ThromboGenics NV's ocriplasmin as a treatment for vitreomacular adhesion, an aging-related vision problem that can lead to blindness.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.
Learn more about writing for us